PMC members shape and advance the future of personalized medicine.
March 02 | Business of Biotech Conference 2018
In a white paper titled Personalized Medicine and Value Assessment Frameworks: Context, Considerations, and Next Steps, PMC contends that most value assessment frameworks still make sweeping conclusions about the economic worth of a particular treatment based almost exclusively on population averages. As a result, the paper contends, most value assessment frameworks could unintentionally discourage payers and providers from considering important information about a patient's biology, values and preferences that can improve health outcomes — especially when value assessment frameworks influence the coverage and payment decisions that determine whether patients have access to treatment options that will work for them.
» Personalized Medicine and Value Assessment Frameworks: Context, Considerations, and Next Steps (PDF)
In response to a Wall Street Journal op-ed and request for information about innovative ways to pay for and deliver health care in the U.S., PMC has encouraged the Centers for Medicare & Medicaid Services (CMS) to spearhead models that empower physicians to move away from the current standard of care when patient outcomes can be improved by tailoring care to a patient's genetics and other factors. In keeping with PMC's mission to underline the significance of personalized medicine to patients and the health system, the Coalition's comment letter contends that personalized medicine products and services can increase the overall value of dollars spent by improving health outcomes.
» PMC comment letter (PDF)